February 8, 2026 11:07 AM
Dr Reddys Laboratories Ltd Tumbles -0.30% in Today's Trading Session
After a -0.30% decline, Dr Reddys Laboratories Ltd shares are now trading at 1241.20. The stock has a PE ratio of 18.7600, an ROE of 16.0277 and a debt to equity ratio of 0.1625.
February 8, 2026 10:09 AM
Dr Reddys Laboratories Ltd Stock Nosedives Today
Dr Reddys Laboratories Ltd stock price decreased by -0.30%, with the current market value at 1241.20 per share. Investors are assessing the stock's potential for recovery and future growth prospects.
February 8, 2026 9:09 AM
Dr Reddys Laboratories Ltd Stock Drops in Today's Trading Session
Dr Reddys Laboratories Ltd's share price has dropped by -0.30%, a development that warrants careful analysis. Presently trading at 1241.20, investors are assessing whether this presents an opportunity or a risk.
February 8, 2026 8:09 AM
Dr Reddys Laboratories Ltd Stock Slides Today
Dr Reddys Laboratories Ltd observed a -0.30% decrease in its share price, a situation that merits attention. As of now, it's actively trading at 1241.20. The stock has a PE ratio of 18.7600, an ROE of 16.0277 and a debt to equity ratio of 0.1625.
February 8, 2026 7:09 AM
Dr Reddys Laboratories Ltd Share Price Falls -0.30% in Today's Trading Session
Dr Reddys Laboratories Ltd witnessed a -0.30% drop in its share price and is currently trading at 1241.20. With the stock's PE at 18.7600 and the industry PE at 31.9912, investors are weighing their options.
February 8, 2026 6:09 AM
Today's Trading Session: Dr Reddys Laboratories Ltd Stock Falls
With a -0.30% decrease, Dr Reddys Laboratories Ltd's share price is now at 1241.20. The stock is currently trading at a PE of 18.7600, while the industry PE is 31.9912, prompting investors to assess its value proposition.
February 8, 2026 5:08 AM
Today's Trading Session: Dr Reddys Laboratories Ltd Share Price Declines by -0.30%
Dr Reddys Laboratories Ltd experienced a -0.30% downturn in its share price, and it's currently trading at 1241.20. This situation is generating interest among value investors who are evaluating the stock's potential.